人福医药（600079）公告，控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签 发的RFUS-949片《药物临床试验批准通知书》。RFUS-949为宜昌人福研发的新分子实体，临床上拟用 于急慢性疼痛的治疗。截至目前，宜昌人福在该项目上的累计研发投入约为1500万元人民币。 ...

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

证券代码：600079 证券简称：人福医药 编号：临 2025-067 号 人福医药集团股份公司 关于黄体酮软胶囊获得药品注册证书的公告 目前该项目累计研发投入约为人民币2,900万元，九珑人福将黄体酮软胶囊委托给公司全 资子公司人福普克药业（武汉）有限公司生产。根据米内网数据显示，2024年度黄体酮 软胶囊全国销售额（统计范围包括城市公立医院、县级公立医院、城市药店）约为人民 币3.72亿元，主要厂商包括Besins Healthcare S.A.、浙江爱生药业有限公司、浙江医药股 份有限公司新昌制药厂等。 本次黄体酮软胶囊获批，标志着公司具备了在中国市场销售该药品的资格。该产品 进一步丰富了公司的产品线，其上市销售将给公司带来积极影响。九珑人福将根据市场 需求情况，着手安排黄体酮软胶囊的生产上市。该产品未来的具体销售情况可能受到行 业政策、市场环境等因素影响，具有不确定性，敬请广大投资者谨慎决策，注意防范投 资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"）控股子公司武汉九 ...

Core Viewpoint - The announcement highlights that Renfu Pharmaceutical's subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., has received approval for the registration certificate of Progesterone Soft Capsules from the National Medical Products Administration, indicating a significant development in the company's product pipeline [1] Group 1: Company Developments - Renfu Pharmaceutical's subsidiary has received the drug registration certificate for Progesterone Soft Capsules, which are used to treat dysfunctions caused by progesterone deficiency and assist in pregnancy [1] - The company submitted the marketing authorization application for the product in December 2023, which has been accepted [1] - Cumulative R&D investment for this project has reached approximately RMB 29 million [1] Group 2: Market Insights - According to data from Minet, the projected national sales for Progesterone Soft Capsules in 2024 are approximately RMB 372 million [1] - Major competitors in the market include Besins Healthcare S.A., Zhejiang Aisheng Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. [1]

Core Insights - The Ministry of Industry and Information Technology has announced the preliminary list of key pilot platforms for nurturing, with six platforms from the Optics Valley included, covering pharmaceuticals, industrial mother machines, integrated circuits, and common needs, accounting for over 60% of the total selected in the province [1][3]. Group 1: Pilot Platforms Overview - The first batch of key pilot platforms includes 242 platforms nationwide, spanning six critical manufacturing sectors essential for high-quality development [3]. - The Jiufeng Mountain Laboratory compound semiconductor pilot platform is equipped with over 500 advanced process and testing devices, focusing on optical, next-generation communication, and power electronics applications, attracting over 500 enterprises and research institutions for collaboration [3][5]. Group 2: Investment and Services - The National Digital Design and Manufacturing Innovation Center's pilot platform has a total investment of approximately 500 million yuan, with 298 sets of pilot equipment, serving nearly 200 clients with contracts exceeding 500 million yuan [5]. - The Dingkang Biological recombinant protein drug pilot platform has provided production services for over 50 products from more than 40 clients, with samples undergoing clinical trials in over 30 countries and regions [5]. Group 3: Importance of Pilot Platforms - The success of pilot testing is crucial for the industrialization of technological achievements, with a success rate of 80% for those that undergo pilot testing compared to only 30% for those that do not [5]. - The number of pilot platforms reflects the local industry's ability to transform technology, indicating the overall development level of the local industry [5][8]. Group 4: Future Development - The Optics Valley has established 61 city-level registered technology achievement transformation pilot platforms, accounting for nearly 30% of the total, primarily in core industries such as new-generation information technology, life health, and high-end equipment [8]. - The East Lake High-tech Zone plans to enhance the pilot platform system, strengthen platform capabilities, and accelerate the integration of technological and industrial innovation for high-quality development [8].

Market Overview - The Shanghai Composite Index closed at 3348.37 points, above the annual line, with a decline of 0.94% [1] - The total trading volume of A-shares reached 1,182.564 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including: - Pruis (4.48% deviation) - Yingjie Electric (3.80% deviation) - Boying Special Welding (3.01% deviation) [1] - Stocks with smaller deviations just above the annual line include: - Shuangjian Co., Ltd. - Rhine Biology - Bull Group [1] Top Performers - The top three stocks with the highest deviation rates from the annual line are: 1. Pruis: 5.17% increase, 8.64% turnover rate, latest price 30.12 yuan 2. Yingjie Electric: 5.80% increase, 8.35% turnover rate, latest price 48.50 yuan 3. Boying Special Welding: 3.28% increase, 6.03% turnover rate, latest price 22.70 yuan [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Fosa Technology: 3.03% increase, 8.32% turnover rate, latest price 32.31 yuan - Shandong Haihua: 5.57% increase, 6.80% turnover rate, latest price 5.88 yuan - Renfu Pharmaceutical: 3.06% increase, 2.53% turnover rate, latest price 20.88 yuan [1]

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3372.33 points, with a slight decline of -0.23% [1] - The total trading volume of A-shares today is 838.849 billion yuan [1] Stocks Breaking Annual Line - A total of 68 A-shares have surpassed their annual line today, with notable stocks including: - Puris (乖离率 6.48%) - Aisen Co., Ltd. (乖离率 5.81%) - Fosa Technology (乖离率 4.02%) [1] Stocks with Significant Deviation - The stocks with the largest deviation from the annual line include: - Puris: Today's price increased by 7.19% to 30.70 yuan - Aisen Co., Ltd.: Today's price increased by 7.47% to 42.00 yuan - Fosa Technology: Today's price increased by 4.30% to 32.71 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance and their respective deviations include: - Yao Stone Technology: 3.77% increase, 3.51% deviation - Fuling Power: 6.24% increase, 3.42% deviation - Yingjie Electric: 5.37% increase, 3.38% deviation [1] Summary of Stocks with Minor Deviations - Stocks with minor deviations from the annual line include: - Huayang Intelligent: 4.58% increase, 2.48% deviation - Boying Special Welding: 2.32% increase, 2.06% deviation - Stone Technology: 2.02% increase, 1.96% deviation [1]

证券代码：600079 证券简称：人福医药 编号：临 2025-066 号 人福医药集团股份公司 关于甲泼尼龙片获得药品注册证书的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 五、注册分类：化学药品4类 六、申请事项：药品注册（境内生产） 七、药品批准文号：国药准字H20254178 八、药品批准文号有效期：至2030年05月12日 九、上市许可持有人：武汉九珑人福药业有限责任公司 十、药品生产企业：武汉九珑人福药业有限责任公司 人福医药集团股份公司（以下简称"公司"）控股子公司武汉九珑人福药业有限责 任公司（以下简称"九珑人福"，公司控股子公司湖北葛店人福药业有限责任公司持有 其100%的股权）近日收到国家药品监督管理局核准签发的甲泼尼龙片的《药品注册证 书》。现将批件主要内容公告如下： 一、药品名称：甲泼尼龙片 二、证书编号：2025S01369 三、剂型：片剂 四、规格：4mg 十一、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-065 号 人福医药集团股份公司 四、规格：重酒石酸氢可酮5mg与布洛芬200mg、重酒石酸氢可酮7.5mg与布洛芬 200mg 五、注册分类：化学药品3类 关于氢可酮布洛芬片获得药品注册证书的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"）控股子公司宜昌人福药业有限责任 公司（以下简称"宜昌人福"，公司持有其80%的股权）近日收到国家药品监督管理 局核准签发的氢可酮布洛芬片的《药品注册证书》。现将批件主要内容公告如下： 一、药品名称：氢可酮布洛芬片 六、申请事项：药品注册（境内生产） 七、药品批准文号：国药准字H20254118、国药准字H20254119 八、药品批准文号有效期：至2030年05月12日 九、上市许可持有人：宜昌人福药业有限责任公司 十、药品生产企业：宜昌人福药业有限责任公司 十一、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册 ...

Core Viewpoint - The approval of Methylprednisolone tablets by the National Medical Products Administration marks a significant milestone for the company, allowing it to sell the product in the Chinese market and enhancing its product portfolio [1] Group 1: Product Approval - The company's subsidiary, Jiulong Renfu, has received the drug registration certificate for Methylprednisolone tablets [1] - The product is indicated for the treatment of various diseases, including rheumatic diseases, collagen diseases, and skin diseases [1] Group 2: Financial and Market Impact - The company submitted the marketing authorization application in July 2024, which has been accepted [1] - Cumulative R&D investment for this project has reached approximately 12 million yuan [1] - According to data from Minet, the estimated national sales for Methylprednisolone tablets in 2024 is around 200 million yuan [1] Group 3: Strategic Implications - The approval signifies the company's capability to market the drug in China, thereby enriching its product line [1]